Why is this study being done?This study aims to explore ways to support caregivers of individuals with dementia in managing stress and improving their overall well-being. By understanding their challenges and needs, we hope to develop effective strategies and resources to enhance their health and quality of life.Who can take part?Formal caregivers (paid employees/volunteers who provide care in a formal setting) and informal caregivers (wives, husbands, partners, family members and friends who provide unpaid care) of an individual or loved one living with dementia.  

What is the goal of this study?Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The purpose of this study is to determine the safety and efficacy of oral ifetroban compared to placebo in subjects with IPF. THIS STUDY IS ENROLLING BY INVITATION ONLY  

What is the goal of this study?The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.The main question the study aims to answer is:• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.The study also aims to answer:• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. THIS STUDY IS ENROLLING BY INVITATION ONLY

What is the purpose of this study?The study will investigate molecular markers associated with dental implant diseases like peri-implantitis to elucidate the mechanistic pathway involved. •    The primary goal of this study is to use GCF or PICF to analyze the microflora present around implants in disease condition and compare it to healthy samples. •    The secondary objective will be to compare oxylipin from GCF or PICF for immune markers and lipid metabolite markers between those of implant diseases and healthy samples. •    A tertiary objective will be to study the rate of healing for each of these dental wounds based on the molecular markers in primary and secondary objectives. THIS STUDY IS ENROLLING BY INVITATION ONLY - Patients who have good gingival health around implants, periimplant mucositis and periimplantitis, who are scheduled for a visit to the Graduate Periodontal Clinic at IUSD and who have an existing implant will be approached by a study team member to determine interest and qualification for participation in the study. Those expressing inerest will be consented prior to the initiation of any study procedures.

What is this study about?The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.THIS STUDY IS ENROLLING BY INVITATION ONLY

What is the purpose of this study?This phase III trial tests how well adding dinutuximab to induction chemotherapy along with standard of care surgery radiation and stem cell transplantation works for treating children with newly diagnosed high risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. Chemotherapy drugs such as cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, dexrazoxane, doxorubicin, temozolomide, irinotecan and isotretinoin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. During induction, chemotherapy and surgery are used to kill and remove as much tumor as possible. During consolidation, very high doses of chemotherapy are given to kill any remaining cancer cells. This chemotherapy also destroys healthy bone marrow, where blood cells are made. A stem cell transplant is a procedure that helps the body make new healthy blood cells to replace the blood cells that may have been harmed by the cancer and/or chemotherapy. Radiation therapy is also given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of induction. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632